DOCSLIB.ORG

Management of Chronic Tension-Type Headache with Tricyclic Antidepressant Medication, Stress Management Therapy, and Their Combination a Randomized Controlled Trial

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Management of Chronic Tension-Type Headache with Tricyclic Antidepressant Medication, Stress Management Therapy, and Their Combination a Randomized Controlled Trial ORIGINAL CONTRIBUTION Management of Chronic Tension-Type Headache With Tricyclic Antidepressant Medication, Stress Management Therapy, and Their Combination A Randomized Controlled Trial Kenneth A. Holroyd, PhD Context Chronic tension-type headaches are characterized by near-daily head- Francis J. O’Donnell, DO aches and often are difficult to manage in primary practice. Behavioral and pharma- Michael Stensland, MS cological therapies each appear modestly effective, but data are lacking on their sepa- rate and combined effects. Gay L. Lipchik, PhD Objective To evaluate the clinical efficacy of behavioral and pharmacological thera- Gary E. Cordingley, MD, PhD pies, singly and combined, for chronic tension-type headaches. Bruce W. Carlson, PhD Design and Setting Randomized placebo-controlled trial conducted from August 1995 to January 1998 at 2 outpatient sites in Ohio. ENSION-TYPE HEADACHES OF- Participants Two hundred three adults (mean age, 37 years; 76% women) with ten occur every day or nearly diagnosis of chronic tension-type headaches (mean, 26 headache d/mo). every day in individuals who 1-3 Interventions Participants were randomly assigned to receive tricyclic antidepres- seek treatment, but head- sant (amitriptyline hydrochloride, up to 100 mg/d, or nortriptyline hydrochloride, up Taches must occur 15 or more days per to 75 mg/d) medication (n=53), placebo (n=48), stress management (eg, relaxation, month for at least 6 months to meet In- cognitive coping) therapy (3 sessions and 2 telephone contacts) plus placebo (n=49), ternational Headache Society diagnos- or stress management therapy plus antidepressant medication (n=53). tic criteria for chronic rather than epi- Main Outcome Measures Monthly headache index scores calculated as the mean 4 sodic tension-type headache. The 1-year of pain ratings (0-10 scale) recorded by participants in a daily diary 4 times per day; num- prevalence rate for chronic tension- ber of days per month with at least moderate pain (pain rating $5), analgesic medica- type headache in the general popula- tion use, and Headache Disability Inventory scores, compared by intervention group. tion is about 3% in women and 1.5% in Results Tricyclic antidepressant medication and stress management therapy each pro- 5,6 men, with just less than half of those duced larger reductions in headache activity, analgesic medication use, and headache- with chronic tension-type headache re- related disability than placebo, but antidepressant medication yielded more rapid im- porting headache-related impairment in provements in headache activity. Combined therapy was more likely to produce clinically work performance. Chronic tension- significant ($50%) reductions in headache index scores (64% of participants) than type headaches are a risk factor for the antidepressant medication (38% of participants; P=.006), stress management therapy overuse of analgesic medications and (35%; P=.003), or placebo (29%; P=.001). On other measures the combined therapy and its 2 component therapies produced similar outcomes. thus the development of analgesic abuse headaches.2,4,6,7 Continuous headaches Conclusions Our results indicate that antidepressant medication and stress man- and frequent comorbid psychiatric or an- agement therapy are each modestly effective in treating chronic tension-type head- algesic use problems often render aches. Combined therapy may improve outcome relative to monotherapy. chronic tension-type headaches diffi- JAMA. 2001;285:2208-2215 www.jama.com cult to manage in primary practice.1,2,8,9 Tricyclic antidepressants are the pri- However, recent trials have reported Author Affiliations: Department of Psychology (Drs Holroyd, Lipchik, and Carlson and Mr Stensland) and mary drug therapy for chronic tension- little (#30%) or no improvement in College of Osteopathic Medicine (Dr Cordingley), Ohio type headache, with amitriptyline hy- chronic tension-type headaches13-15 with University, Athens; and Headache Treatment and Re- 2,9-12 search (Drs Holroyd, O’Donnell, and Lipchik) and Or- drochloride the first-line treatment. amitriptyline. Additional information thoNeuro (Dr O’Donnell), Westerville, Ohio. Dr Lip- is therefore needed to confirm the ben- chik is now with St Vincent Health Center, Erie, Pa. efits of this widely used medication for Corresponding Author and Reprints: Kenneth A. Hol- See also Patient Page. royd, PhD, 225 Porter Hall, Athens, OH 45701 (e-mail: chronic tension-type headache. [email protected]). 2208 JAMA, May 2, 2001—Vol 285, No. 17 (Reprinted) ©2001 American Medical Association. All rights reserved. Downloaded From: http://jama.jamanetwork.com/ on 02/25/2013 ANTIDEPRESSANTS AND STRESS MANAGEMENT FOR HEADACHE Behavioral therapies, primarily re- Figure 1. Participant Flow in the Study laxation, biofeedback, and cognitive be- havior (stress management) therapies 409 Patients Evaluated appear to be effective in managing ten- 16-24 sion-type headache. However, tri- 206 Excluded als of behavioral therapies also have methodological shortcomings: results 203 Randomized typically have not been reported spe- cifically for participants with chronic 53 Assigned to Receive 49 Assigned to Receive 53 Assigned to Receive 48 Assigned to Receive Antidepressant Stress Management Antidepressant Placebo tension-type headache and few trials Medication Therapy Plus Placebo Medication Plus Stress have included placebo controls.25 Ad- Management Therapy ditional information is thus needed to 5 Dropped Out 11 Dropped Out 8 Dropped Out 10 Dropped Out confirm the effectiveness of behav- 1 Adverse Effects 1 Adverse Effects 1 Adverse Effects 2 Poor Response ioral therapy for chronic tension-type 1 Lost to Follow-up 2 Lost to Follow-up 1 Lost to Follow-up 2 Adverse Effects 3 Other 3 Lack of Time 3 Lack of Time 1 Lost to Follow-up headache. The possibility that behav- 5 Other 3 Other 1 Lack of Time ioral therapy can enhance outcomes ob- 4 Other tained with antidepressant medica- 13,24 48 Evaluated at 1 mo 38 Evaluated at 1 mo 45 Evaluated at 1 mo 38 Evaluated at 1 mo tion (AM) also needs to be evaluated. After Treatment (Dose After Treatment (Dose After Treatment (Dose After Treatment (Dose This study was intended to evaluate Adjustment) Phase Adjustment) Phase Adjustment) Phase Adjustment) Phase the separate and combined effects of tri- 4 Dropped Out 4 Dropped Out 5 Dropped Out 12 Dropped Out cyclic antidepressant (amitriptyline and 1 Poor Response 1 Poor Response 1 Poor Response 8 Poor Response 1 Lost to Follow-up 1 Lost to Follow-up 4 Other 1 Adverse Effects nortriptyline hydrochloride) medica- 2 Other 2 Other 3 Lost to Follow-up tion (AM) and brief stress manage- ment therapy (SMT) for chronic ten- 44 Evaluated at 6 mo 34 Evaluated at 6 mo 40 Evaluated at 6 mo 26 Evaluated at 6 mo After Treatment (Dose After Treatment (Dose After Treatment (Dose After Treatment (Dose sion-type headache. Adjustment) Phase Adjustment) Phase Adjustment) Phase Adjustment) Phase METHODS procedures approved by the Ohio Uni- sequent 6-month evaluation phase, clinic Participants versity Human Subjects Committee. visits were scheduled 1, 3, and 6 months Participants were recruited from pri- following completion of the treatment mary practice referrals and by local ad- Study Design and Treatments (dose adjustment) phase. The 1- and vertisements at 2 outpatient sites. In- After completing the baseline assess- 6-month evaluations included review of clusion criteria were age between 18 ment that included 1 month of head- 1 month of daily headache and medica- and 65 years and receipt of an Interna- ache and medication diary recordings, tion diaries, neurological evaluation, and tional Headache Society diagnosis of participants were randomly assigned in psychosocial testing. The 3-month chronic tension-type headache4 at 2 blocks of 4 participants to 4 treatments evaluation included only medication separate evaluations. Exclusion crite- (FIGURE 1): AM, placebo, SMT plus pla- checks and brief evaluation. ria were: International Headache Soci- cebo, and SMT plus AM. The AM and Tricyclic Antidepressant Medica- ety diagnosis of analgesic-abuse head- placebo therapies were administered in tion and Placebo. In this double-blind aches4; current use of AM or other a standard double-blind fashion. Treat- protocol, we attempted to maximize the prophylactic medication for head- ment conditions were blinded only for efficacy and tolerability of AM by using ache, or regular ($15 d/mo) use of anx- the medication component and not for a low starting dose and recommended iolytic medication; current psycho- the administration of SMT. This trial was target doses for the treatment of chronic therapy; current or planned pregnancy conducted between August 1995 and tension-type headache,11,26-29 by treat- or breastfeeding; medical contraindi- January 1998. ing participants who were unable to tol- cation to amitriptyline; migraine head- Each treatment protocol required 3 erate amitriptyline with nortriptyline and ache more than 1 day a month; pain dis- clinic visits and 2 telephone contacts by use of an adherence intervention de- order (eg, arthritis) other than headache during the 2-month treatment (dose ad- signed to increase AM adherence.30 as primary pain problem; psychiatric justment) phase, during which SMT was Treatment was initiated with 1 lead-in (eg, suicide risk) or medical disorder administered and the medication dose capsule of medication to be taken at bed- requiring immediate treatment; and fail- was adjusted. Clinic visits were sched- time (12.5
Load more

Recommended publications
  • Still the Leading Antidepressant After 40 Years of Randomised Controlle
    BRITISH JOURNAL OF PSYCHIATRY "2001), 178, 129^144 REVIEW ARTICLE Amitriptyline vv.therest:stilltheleading METHOD Inclusion criteria antidepressant after 40 years of randomised All RCTs comparing amitriptyline with any y other tricyclic,heterocyclic or SSRI were in- controlled trials cluded. Crossover studies were excluded. Studies adopting any criteria to define CORRADO BARBUI and MATTHEW HOTOPF patients suffering from depression were included; a concurrent diagnosis of another psychiatric disorder was not considered an exclusion criterion. Trials in patients with depression with a concomitant medical ill- Background Tricyclic antidepressants Amitriptyline is one of the first `reference' ness were not included in this review. have similar efficacy and slightly lower tricyclic antidepressants TCAs). Over the past 40 years a number of newer tricyclics, tolerability than selective serotonin Search strategy heterocyclics and selective serotonin re- Relevant studies were located by searching reuptakeinhibitorsreuptake inhibitors SSRIs).However, uptake inhibitors SSRIs) have been intro- the Cochrane Collaboration Depression, there are no systematic reviews assessing duced Garattini et aletal,1998). Despite Anxiety and Neurosis Controlled Trials several large systematic reviews comparing amitriptyline, the reference tricyclic drug, Register CCDANCTR). This specialised tricyclics and SSRIs there is no clear agree- vv. other tricyclics and SSRIs directly. register is regularly updated by electronic ment over first-line treatment of depression Medline,Embase,PsycINFO,LILACS, SongSong et aletal,1993; Anderson & Tomenson, Aims ToreviewTo review the tolerability and Psyndex,CINAHL,SIGLE) and non-electro- 1995; Montgomery & Kasper,1995; efficacy of amitriptyline inthe nicnicliterature searches. The register was HotopfHotopf et aletal,1996; Canadian Coordinating management of depression. searched using the following terms: Office for Health Technology Assessment, AMITRIPTYLIN**AMITRIPTYLIN oror AMITRILAMITRIL oror ELA-ELA- 19971997aa).
    [Show full text]
  • Use of Amitriptyline for the Treatment of Chronic Tension-Type Headache
    Med Oral Patol Oral Cir Bucal. 2008 Sep1;13(9):E567-72. Amitriptyline and chronic tension-type headache Med Oral Patol Oral Cir Bucal. 2008 Sep1;13(9):E567-72. Amitriptyline and chronic tension-type headache Publication Types: Review Use of amitriptyline for the treatment of chronic tension-type headache. Review of the literature Eulalia Torrente Castells 1, Eduardo Vázquez Delgado 2, Cosme Gay Escoda 3 (1) Odontóloga. Residente del Máster de Cirugía Bucal e Implantología Bucofacial. Facultad de Odontología de la Universidad de Barcelona (2) Odontólogo. Profesor Asociado de Cirugía Bucal. Profesor responsable de la Unidad de Patología de la ATM y Dolor Bucofacial del Máster de Cirugía Bucal e Implantología Bucofacial. Facultad de Odontología de la Universidad de Barcelona. Especialista de la Unidad de Patología de la ATM y Dolor Bucofacial del Centro Médico Teknon. Barcelona (3) Médico-Estomatólogo y Cirujano Maxilofacial. Catedrático de Patología Quirúrgica Bucal y Maxilofacial. Director del Máster de Cirugía Bucal e Implantología Bucofacial. Facultad de Odontología de la Universidad de Barcelona. Co-director de la Unidad de Patología de la ATM y Dolor Bucofacial del Centro Médico Teknon. Barcelona Correspondence: Prof. Cosme Gay Escoda Centro Médico Teknon C/Vilana nº 12 08022 Barcelona E-mail: [email protected] Torrente-Castells E, Vázquez-Delgado E, Gay-Escoda C. Use of amitrip- Received: 28/09/2007 tyline for the treatment of chronic tension-type headache. Review of the Accepted: 11/07/2008 literature. Med Oral Patol Oral Cir Bucal. 2008 Sep1;13(9):E567-72. © Medicina Oral S. L. C.I.F. B 96689336 - ISSN 1698-6946 Indexed in: http://www.medicinaoral.com/medoralfree01/v13i9/medoralv13i9p567.pdf -Index Medicus / MEDLINE / PubMed -EMBASE, Excerpta Medica -SCOPUS -Indice Médico Español -IBECS Abstract Amitriptyline is a tricyclic antidepressant, considered the treatment of choice for different types of chronic pain, including chronic myofascial pain.
    [Show full text]
  • Pharmacokinetic and Pharmacodynamic Interactions Between Antiepileptics and Antidepressants Domenico Italiano University of Messina, Italy
    University of Kentucky UKnowledge Psychiatry Faculty Publications Psychiatry 11-2014 Pharmacokinetic and Pharmacodynamic Interactions between Antiepileptics and Antidepressants Domenico Italiano University of Messina, Italy Edoardo Spina University of Messina, Italy Jose de Leon University of Kentucky, [email protected] Right click to open a feedback form in a new tab to let us know how this document benefits oy u. Follow this and additional works at: https://uknowledge.uky.edu/psychiatry_facpub Part of the Psychiatry and Psychology Commons Repository Citation Italiano, Domenico; Spina, Edoardo; and de Leon, Jose, "Pharmacokinetic and Pharmacodynamic Interactions between Antiepileptics and Antidepressants" (2014). Psychiatry Faculty Publications. 40. https://uknowledge.uky.edu/psychiatry_facpub/40 This Article is brought to you for free and open access by the Psychiatry at UKnowledge. It has been accepted for inclusion in Psychiatry Faculty Publications by an authorized administrator of UKnowledge. For more information, please contact [email protected]. Pharmacokinetic and Pharmacodynamic Interactions between Antiepileptics and Antidepressants Notes/Citation Information Published in Expert Opinion on Drug Metabolism & Toxicology, v. 10, Issue 11, p. 1457-1489. © 2014 Taylor & Francis Group This is an Accepted Manuscript of an article published by Taylor & Francis Group in Expert Opinion on Drug Metabolism & Toxicology in Nov. 2014, available online: http://www.tandfonline.com/10.1517/ 17425255.2014.956081 Digital Object Identifier (DOI) http://dx.doi.org/10.1517/17425255.2014.956081 This article is available at UKnowledge: https://uknowledge.uky.edu/psychiatry_facpub/40 1 This is an Accepted Manuscript of an article published by Taylor & Francis Group in Expert Opinion on Drug Metabolism & Toxicology in Nov.
    [Show full text]
  • 1 Supplemental Figure 1: Illustration of Time-Varying
    Supplemental Material Table of Contents Supplemental Table 1: List of classes and medications. Supplemental Table 2: Association between benzodiazepines and mortality in patients initiating hemodialysis (n=69,368) between 2013‐2014 stratified by age, sex, race, and opioid co‐dispensing. Supplemental Figure 1: Illustration of time‐varying exposure to benzodiazepine or opioid claims for one person. Several sensitivity analyses were performed wherein person‐day exposure was extended to +7 days, +14 days, and +28 days beyond the outlined periods above. 1 Supplemental Table 1: List of classes and medications. Class Medications Short‐acting benzodiazepines Alprazolam, estazolam, lorazepam, midazolam, oxazepam, temazepam, and triazolam Long‐acting benzodiazepines chlordiazepoxide, clobazam, clonazepam, clorazepate, diazepam, flurazepam Opioids alfentanil, buprenorphine, butorphanol, codeine, dihydrocodeine, fentanyl, hydrocodone, hydromorphine, meperidine, methadone, morphine, nalbuphine, nucynta, oxycodone, oxymorphone, pentazocine, propoxyphene, remifentanil, sufentanil, tapentadol, talwin, tramadol, carfentanil, pethidine, and etorphine Antidepressants citalopram, escitalopram, fluoxetine, fluvozamine, paroxetine, sertraline; desvenlafaxine, duloxetine, levomilnacipran, milnacipran, venlafaxine; vilazodone, vortioxetine; nefazodone, trazodone; atomoxetine, reboxetine, teniloxazine, viloxazine; bupropion; amitriptyline, amitriptylinoxide, clomipramine, desipramine, dibenzepin, dimetacrine, dosulepin, doxepin, imipramine, lofepramine, melitracen,
    [Show full text]
  • Nozinan ® Tablets Levomepromazine Maleate
    Nozinan® Tablets levomepromazine maleate Consumer Medicine Information (CMI) What is in this leaflet Before you take it Tell your doctor or pharmacist if you are pregnant or intend to This leaflet answers some common become pregnant. questions about Nozinan. When you must not take it Like most medicines of this kind, Nozinan is not recommended to be It does not contain all the available Do not take Nozinan if you have: used during pregnancy. Your doctor information. It does not take the or pharmacist will discuss the risks place of talking to your doctor or • liver disease and benefits of taking it if you are pharmacist. • heart disease pregnant. All medicines have risks and benefits. • urinary or prostate problems Tell your doctor or pharmacist if Your doctor has weighed the risks of you are breastfeeding or planning • increased pressure in the eye you taking this medicine against the to breastfeed. (glaucoma) benefits he expects it will have for It is not known whether Nozinan you. • a history of a lack of white blood passes into breast milk. Your doctor If you have any concerns about cells (agranulocytosis) or pharmacist will discuss the risks and benefits of taking it if you are taking this medicine, ask your Do not take Nozinan if you are breastfeeding or planning to doctor or pharmacist. allergic to it or any of the breastfeed. Keep this leaflet with the medicine. ingredients listed at the end of this leaflet. You may need to read it again. Tell your doctor or pharmacist if Some symptoms of an allergic you have or have had any medical reaction include skin rash, itching, conditions, especially the following: shortness of breath or swelling of the • heart disease face, lips or tongue, which may cause What Nozinan is used difficulty in swallowing or breathing.
    [Show full text]
  • Esketamine for the Treatment of Treatment-Resistant Depression: Effectiveness and Value
    Esketamine for the Treatment of Treatment-Resistant Depression: Effectiveness and Value Evidence Report May 9, 2019 Prepared for ©Institute for Clinical and Economic Review, 2019 The University of Illinois at Chicago College of ICER Staff and Consultants Pharmacy’s Center for Pharmacoepidemiology and Pharmacoeconomic Research* Steven J. Atlas, MD, MPH Daniel R. Touchette, PharmD, MA Associate Professor of Medicine Professor of Pharmacy Harvard Medical School, Boston Assistant Director, Center for Pharmacoepidemiology Director, Practice Based Research & Quality and Pharmacoeconomic Research Improvement University of Illinois at Chicago Division of General Internal Medicine Massachusetts General Hospital, Boston Nicole Boyer, PhD Research Fellow Foluso Agboola, MBBS, MPH University of Chicago Director, Evidence Synthesis Institute for Clinical and Economic Review Brian Talon, PharmD PhD Student University of Illinois at Chicago Katherine Fazioli Senior Research Assistant Bob G. Schultz, PharmD Institute for Clinical and Economic Review PhD Student and Research Fellow University of Illinois at Chicago Varun M. Kumar, MBBS, MPH, MSc Associate Director of Health Economics Institute for Clinical and Economic Review *The role of the University of Illinois at Chicago College of Ellie Adair, MPA Pharmacy’s Center for Pharmacoepidemiology and Program Manager Pharmacoeconomic Research is limited to the development of the cost-effectiveness model, and the resulting ICER reports do not Institute for Clinical and Economic Review necessarily represent the views of the UIC. David Rind, MD Chief Medical Officer Institute for Clinical and Economic Review Steve Pearson, MD, MSc President Institute for Clinical and Economic Review Date of Publication: May 9, 2019 Steven Atlas served as the lead author for the report.
    [Show full text]
  • Resistant Depression: Effectiveness and Value
    Esketamine for the Treatment of Treatment- Resistant Depression: Effectiveness and Value Draft Evidence Report March 21, 2019 Prepared for ©Institute for Clinical and Economic Review, 2019 The University of Illinois at Chicago College of ICER Staff and Consultants Pharmacy’s Center for Pharmacoepidemiology and Pharmacoeconomic Research* Steven J. Atlas, MD, MPH Daniel R. Touchette, PharmD, MA Associate Professor of Medicine Professor of Pharmacy Harvard Medical School, Boston Assistant Director, Center for Pharmacoepidemiology Director, Practice Based Research & Quality and Pharmacoeconomic Research Improvement University of Illinois at Chicago Division of General Internal Medicine Massachusetts General Hospital, Boston Nicole Boyer, PhD Research Fellow Foluso Agboola, MBBS, MPH University of Chicago Director, Evidence Synthesis Institute for Clinical and Economic Review Brian Talon, PharmD PhD Student University of Illinois at Chicago Katherine Fazioli Senior Research Assistant Bob G. Schultz, PharmD Institute for Clinical and Economic Review PhD Student and Research Fellow University of Illinois at Chicago Varun Kumar, MBBS, MPH, MSc Associate Director of Health Economics Institute for Clinical and Economic Review Ellie Adair, MPA Program Manager Institute for Clinical and Economic Review David Rind, MD Chief Medical Officer Institute for Clinical and Economic Review *The role of the University of Illinois at Chicago College of Pharmacy’s Center for Pharmacoepidemiology and Pharmacoeconomic Research is limited to the development of the Steve Pearson, MD, MSc cost-effectiveness model, and the resulting ICER reports do not President necessarily represent the views of the UIC. Institute for Clinical and Economic Review Date of Publication: March 21, 2019 Steve Atlas served as the lead author for the report.
    [Show full text]
  • Carrollton 2017 BEST
    Dr. Justin Northeim Medical Director ________________________________ Medical Director ________________________________ Chief ________________________________ Protocol Effective Date ________________________________ Department License Expiration Date Table of Contents Section One: General Information!..........................................................7 • Aero-medical Transport Guidelines: 7 • Cessation of Efforts: 7 • Consent/Refusal of Treatment: 8 • Controlled Substances: 11 • Do Not Resuscitate (DNR): 12 • EMS Patient Care Report: 14 • Immobilization Standards: 14 • Infectious Disease: 16 • Inter-Hospital Emergency Transfers: 16 • Mass Casualty Incident: 17 • Medical Control: 21 • Ongoing Skills and Competencies: 21 • Out of City Response: 21 • Restraint Policy: 21 • Resuscitation Guidelines: 23 • Run Review Process: 23 • Scope of Practice: 24 • Standing Orders: 25 • Transportation Guidelines: 25 • Unknown Health Care Professional at Scene: 27 Section Two: Patient Assessment!........................................................29 • Capnography: 29 • Initial Patient Assessment: 30 • History and Physical—Medical Patient: 31 • History and Physical—Trauma Patient: 31 • Intravenous Access/Fluids: 31 • Neurological Assessment: 32 • Patient Movement: 33 • Scene Size-Up: 33 • Triage: 34 • Twelve Lead EKG: 34 *These protocols are not to be copied or distributed without written consent from BEST EMS 1 • Vital Signs: 35 Section Three: Medical Protocols!.........................................................37 • Allergic Reactions
    [Show full text]
  • PED-1407 – Pediatric Mental Health
    Pediatric Mental Health Pharmacology Pediatric Mental Health Pharmacology Pediatric Mental Health Pharmacology Pediatric Mental Health Pharmacology W Lawrence Daniels, PhD, RN, CPNP, NRP Christian Psychotherapy Services Nansemond Suffolk Volunteer Rescue Squad South University College of Nursing and Public Health 1 Disclaimer • The presenter has no invested interest in any product or organization described in this presentation. • No funding has been provided by any pharmaceutical company, healthcare organization, or other source to support this presentation. 2 Overview • Neurotransmitter anatomy and physiology • Developmental principles • Common childhood mental illnesses • Classes of psychotropic medications • Specific psychotropic medications • Adverse effects and emergency interventions 3 Peripheral Neuroanatomy A review of the peripheral autonomic nervous system and pharmacology. The effects of central acting pharmaceutics are best understood by how they effect peripheral autonomic nervous system. 4 Peripheral Receptors • Four primary neurotransmitters found in the peripheral autonomic nervous system. – Acetylcholine – Epinephrine – Norepinephrine – Dopamine • Each activates selective receptors on different cells to produce effects. 5 Neurotransmitters of the Peripheral Nervous System • Employed at most junctions of Acetylcholine the peripheral nervous system • Released by most Norepinephrine postganglionic neurons Epinephrine • Released by the adrenal medulla • Serves as a local chemical Dopamine messenger at limited sites 6 Transmitters
    [Show full text]
  • CCDAN Search Strategies (All Antidepressants)
    CCDAN search strategies (all antidepressants) 1. Cochrane Depression, Anxiety and Neurosis Review Group’s Specialized Register (CCDANCTR) #1 (antidepress* or anti-depress* or "anti depress*" or MAOI* or RIMA* or “monoamine oxidase inhibit*” or ((serotonin or norepinephrine or noradrenaline or neurotransmitter* or dopamin*) NEAR (uptake or reuptake or re-uptake or "re uptake")) or SSRI* or SNRI* or NARI* or SARI* or NDRI* or TCA* or tricyclic* or tetracyclic* or pharmacotherap* or psychotropic* or "drug therapy") #2 (Agomelatine or Alaproclate or Amoxapine or Amineptine or Amitriptylin* or Amitriptylinoxide or Atomoxetine or Befloxatone or Benactyzine or Binospirone or Brofaromine or (Buproprion or Amfebutamone) or Butriptyline or Caroxazone or Cianopramine or Cilobamine or Cimoxatone or Citalopram or (Chlorimipramin* or Clomipramin* or Chlomipramin* or Clomipramine) or Clorgyline or Clovoxamine or (CX157 or Tyrima) or Demexiptiline or Deprenyl or (Desipramine* or Pertofrane) or Desvenlafaxine or Dibenzepin or Diclofensine or Dimetacrin* or Dosulepin or Dothiepin or Doxepin or Duloxetine or Desvenlafaxine or DVS-233 or Escitalopram or Etoperidone or Femoxetine or Fluotracen or Fluoxetine or Fluvoxamine or (Hyperforin or Hypericum or “St John*”) or Imipramin* or Iprindole or Iproniazid* or Ipsapirone or Isocarboxazid* or Levomilnacipran or Lofepramine* or (“Lu AA21004” or Vortioxetine) or "Lu AA24530" or (LY2216684 or Edivoxetine) or Maprotiline or Melitracen or Metapramine or Mianserin or Milnacipran or Minaprine or Mirtazapine or Moclobemide
    [Show full text]
  • Antidepressants for Insomnia in Adults (Review)
    Cochrane Database of Systematic Reviews Antidepressants for insomnia in adults (Review) Everitt H, Baldwin DS, Stuart B, Lipinska G, Mayers A, Malizia AL, Manson CCF, Wilson S Everitt H, Baldwin DS, Stuart B, Lipinska G, Mayers A, Malizia AL, Manson CCF, Wilson S. Antidepressants for insomnia in adults. Cochrane Database of Systematic Reviews 2018, Issue 5. Art. No.: CD010753. DOI: 10.1002/14651858.CD010753.pub2. www.cochranelibrary.com Antidepressants for insomnia in adults (Review) Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . ..... 4 BACKGROUND .................................... 6 OBJECTIVES ..................................... 8 METHODS ...................................... 8 Figure1. ..................................... 10 RESULTS....................................... 12 Figure2. ..................................... 14 Figure3. ..................................... 15 Figure4. ..................................... 24 ADDITIONALSUMMARYOFFINDINGS . 27 DISCUSSION ..................................... 32 AUTHORS’CONCLUSIONS . 35 ACKNOWLEDGEMENTS . 35 REFERENCES ..................................... 36 CHARACTERISTICSOFSTUDIES . 41 DATAANDANALYSES. 95 Analysis 1.1. Comparison 1 Selective serotonin reuptake inhibitors (SSRI) versus other antidepressants, Outcome 1 Subjective measure of sleep quality. ...... 96
    [Show full text]
  • Topical Treatments of Skin Pain Associated with Hidradenitis Supprurativa
    Volume 20 Number 7 July 2014 Review Topical treatments of skin pain: a general review with a focus on hidradenitis suppurativa with topical agents Noah Scheinfeld MD JD Dermatology Online Journal 20 (7): 3 Assistant Clinical Professor of Dermatology Weil Cornel Medical College Correspondence: Noah Scheinfeld 150 West 55th Street NYC NY 10019 (212) 991-6490 [email protected] Abstract Hidradenitis Supprurativa (HS) is a painful chronic follicular disease. Few papers have addressed pain control for this debilitating condition. Possible topical agents include tricyclic antidepressants, opioids, anticonvulsants, NSAIDs, NMDA receptor antagonists, local anesthetics and other agents. The first line agents for the topical treatment of the cutaneous pain of HS are diclonefac gel 1% and liposomal xylocaine 4% and 5% cream or 5% ointment. The chief advantage of topical xylocaine is that is quick acting i.e. immediate however with a limited duration of effect 1-2 hours. The use of topical ketamine, which blocks n- methyl-D-aspartate receptors in a non-competitive fashion, might be a useful tool for the treatment of HS pain. Topical doxepin, which available in a 5% commercially preparation (Zonalon®) , makes patients drowsy and is not useful for controlling the pain of HS . Doxepin is available in a 3% or 3.3% concentration (which causes less drowsiness) from compounding pharmacies and can be used in compounded analgesic preparations with positive effect. Topical doxepin is preferred over use of topical amitriptyline because topical doxepin is more effective. Nevertheless, topical amitriptyline increase of the tactile and mechanical nociceptive thresholds and can be used for topical pain control in compound mixture of analgesics .
    [Show full text]